ijms-logo

Journal Browser

Journal Browser

Biomarkers for Diagnosis and Prognosis in Urological Tumors II

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 4750

Special Issue Editor

Special Issue Information

Dear Colleagues,

When a tumor is diagnosed, many patients are faced with the question of how long they will survive with this condition and how and how fast they have to be treated. Clinical and pathological examinations help to differentiate tumors in terms of their degree of aggressiveness. This may help to make a treatment decision after a tumor diagnosis and to estimate cancer-specific survival. However, individual risk stratification is also subject to some challenges. For example, it is not always possible to find the relevant tumor site in a biopsy, or it is difficult to reach it. Pathological examination can also be interobserver-variable. An example of this is Gleason grading in prostate cancer. In many cases, urological tumors present a heterogeneity that cannot be precisely determined. Therefore, it may happen that tumors which do not differ in their clinical and pathological characteristics have to be treated a different way or have a completely different oncological outcome after treatment.

Genetic analyses may be able to answer these clinical questions. Various methodologies can be used for this purpose. These investigations may involve tumor tissue, adjacent stroma tissue, and urine or blood samples.

For this Special Issue, we are looking for original research article and state-of-the-art reviews which can demonstrate that new or already established genetic markers may be helpful to improve diagnosis or better predict oncological outcome.

Dr. Pierre Tennstedt
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

24 pages, 3084 KiB  
Review
On the Road to Accurate Protein Biomarkers in Prostate Cancer Diagnosis and Prognosis: Current Status and Future Advances
by Yiwu Yan, Su Yeon Yeon, Chen Qian, Sungyong You and Wei Yang
Int. J. Mol. Sci. 2021, 22(24), 13537; https://doi.org/10.3390/ijms222413537 - 17 Dec 2021
Cited by 12 | Viewed by 3982
Abstract
Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide. Molecular biomarkers work in conjunction with existing clinicopathologic tools to help physicians decide who to biopsy, re-biopsy, treat, or re-treat. The past decade has witnessed the commercialization of multiple [...] Read more.
Prostate cancer (PC) is a leading cause of morbidity and mortality among men worldwide. Molecular biomarkers work in conjunction with existing clinicopathologic tools to help physicians decide who to biopsy, re-biopsy, treat, or re-treat. The past decade has witnessed the commercialization of multiple PC protein biomarkers with improved performance, remarkable progress in proteomic technologies for global discovery and targeted validation of novel protein biomarkers from clinical specimens, and the emergence of novel, promising PC protein biomarkers. In this review, we summarize these advances and discuss the challenges and potential solutions for identifying and validating clinically useful protein biomarkers in PC diagnosis and prognosis. The identification of multi-protein biomarkers with high sensitivity and specificity, as well as their integration with clinicopathologic parameters, imaging, and other molecular biomarkers, bodes well for optimal personalized management of PC patients. Full article
(This article belongs to the Special Issue Biomarkers for Diagnosis and Prognosis in Urological Tumors II)
Show Figures

Figure 1

Back to TopTop